Back to Newsroom

Immunexpress Announces Presentations at the 45th Annual Society of Critical Care Medicine Congress on the Utility of SeptiCyte® Lab

SEATTLE, Feb. 10, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data on the utility of SeptiCyte® Lab in both adult and pediatric populations to aid in the clinical assessment of sepsis in critical care patients will be presented at the upcoming 45th Annual Society of Critical Care Medicine Congress on Feb. 21-22 in Orlando, Fla.

 

Read more here.